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One sentence summary: Resolution of copy number changes in African populations 
reveals a complex structural variant that encodes hybrid genes and confers resistance to 
severe malaria. 
 
Abstract: 
The malaria parasite Plasmodium falciparum invades human red blood cells via 
interactions between host and parasite surface proteins. By analyzing genome sequence 
data from human populations, including 1269 individuals from sub-Saharan Africa, we 
identify a diverse array of large copy number variants affecting the host invasion 
receptor genes GYPA and GYPB. We find that a nearby association with severe malaria 
is explained by a complex structural rearrangement involving the loss of GYPB and gain 
of two GYPB-A hybrid genes, which encode a serologically distinct blood group antigen 
known as Dantu. This variant reduces the risk of severe malaria by 40% and has 
recently risen in frequency in parts of Kenya, yet it appears to be absent from west 
Africa. These findings link structural variation of red blood cell invasion receptors with 
natural resistance to severe malaria. 
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Main text: 
Malaria parasites cause human disease by invading and replicating inside red blood 
cells, which can lead to life-threatening complications that are a major cause of 
childhood mortality in Africa (1, 2). The invasion of red blood cells is orchestrated by the 
specific binding of parasite ligands to erythrocyte receptors (3), a stage at which genetic 
variation could influence the progression of infection. Indeed, a human genetic variant 
that prevents erythrocytic expression of the Duffy antigen receptor for chemokines 
(DARC), which is essential for invasion by Plasmodium vivax, is thought to have 
undergone a selective sweep resulting in the present-day absence of P. vivax malaria 
across most of sub-Saharan Africa (4). In contrast the main cause of malaria in Africa, P. 
falciparum, has an expanded family of erythrocyte binding ligands that target a different 
set of human receptors, most of which appear not to be required for invasion (5-7). Two 
such invasion receptors are the glycophorins GYPA and GYPB, which are abundantly 
expressed on the erythrocyte surface and underlie the MNS blood group system (6, 8-
10). The antigenic complexity of this system as well as rates of amino acid substitution 
and levels of diversity in African populations have led to speculation that this locus is 
under evolutionary selection due to malaria (8, 11-13). 
 
In a recent genome-wide association study (GWAS), we identified alleles associated 
with protection from severe malaria on chromosome 4, between FREM3 and the cluster 
of genes encoding GYPE, GYPB and GYPA (14). Although the association signal did not 
extend to these genes and a functional variant was not identified, interpretation and 
further analysis of the association signal was inhibited by several factors. First, the 
GWAS samples were collected at multiple locations in sub-Saharan Africa, where levels 
of human genetic diversity are higher than in other parts of the world. This diversity 
remains underrepresented in genome variation reference panels. Second, the 
	 5	
glycophorin genes are in a region of segmental duplication that is difficult to characterize 
due to high levels of paralogy. Notably, the region is known to harbor structural variation 
that contributes to the MNS blood group system but has not been characterized by next 
generation sequence data (15, 16). Here we aim to capture additional variation in sub-
Saharan African populations, including structural variation, to determine the underlying 
architecture of the association signal in this region. 
 
An African-enriched reference panel in the glycophorin region 
We constructed a reference panel with improved representation of sub-Saharan African 
populations from countries where malaria is endemic. We performed genome 
sequencing of 765 individuals from 10 ethnic groups in the Gambia, Burkina Faso, 
Cameroon and Tanzania, including 207 family trios (100 bp paired end (PE) reads, 
mean coverage 10x; Tables S1, S2). We focused on a region surrounding the observed 
association signal (chr4:140Mb-150Mb; GRCh37 coordinates). Genotypes at single 
nucleotide polymorphism (SNPs) and short indels in the region were called and 
computationally phased (17-19) and combined with Phase 3 of the 1000 Genomes 
Project (20) to obtain a reference panel of 3,269 individuals, including 1,269 Africans 
and a further 157 individuals with African ancestry (Fig. S1; Tables S1, S3). We imputed 
variants from this panel into the published severe malaria GWAS dataset comprising 
4,579 cases of severe malaria and 5,310 population controls from the Gambia, Kenya 
and Malawi and tested for association as described previously (14). The signal of 
association, formerly identified and replicated at SNPs lying between FREM3 and 
GYPE, extends over a region of at least 700 kb, and includes linked variants within 
GYPA and GYPB where association is only apparent with the additional African 
reference data (Fig. S2). 
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Identification of copy number variants 
We next assessed copy number variation in the glycophorin region (defined here as the 
segmental duplication within which the three genes lie) for the sequenced reference 
panel individuals. The high level of sequence identity between the duplicate units 
presents a challenge for short read sequence analysis due to ambiguous mapping (Fig. 
1B) (21). We therefore focused on changes in read depth at sites of high mappability 
and developed a hidden Markov model (HMM) to infer the underlying copy number state 
for each individual in 1600 bp windows. We grouped individuals carrying similar copy 
number paths to define copy number variants (CNVs) and assign individual CNV 
genotypes. 
 
Across the 3,269 samples, we identified eight deletions and eight duplications that were 
found in ≥2 unrelated individuals (referred to below as non-singleton CNVs), as well as 
at least 11 singleton variants (Figs. 1A, S3) (22). For reference, we label these variants 
by copy number type (DEL for deletion, DUP for duplication), and number them in order 
of frequency. To validate the CNV calls we analyzed transmission in family trios and 
observed segregation as expected with few exceptions (Table S4) (22). We also 
compared the CNV calls with the 1000 Genomes Project structural variant analysis (23), 
and found highly consistent copy number inference (98.8% of individuals have the same 
overall copy number call) but substantial improvements to individual genotypes in our 
analysis (Fig. S4) (22). Validation of the breakpoint of the most common variant (DEL1) 
by Sanger sequencing further confirmed the accuracy of our method (Figs. S5, S6 and 
Table S5) (22).  
 
The variants ranged in length from 3.2 kb (the minimum possible with our method) to 
>200 kb and included deletions and duplications of entire genes. Loss of GYPB was a 
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common feature, with five different forms of GYPB deletion among the non-singleton 
CNVs (Fig. 1A). Hybrid gene structures were another common feature, with two non-
singleton CNVs predicted to generate GYPB-A or GYPE-A hybrids (Fig. S7). Some 
variants are predicted to correspond to known MNS blood group antigens while others 
have not previously been reported (Table S6) (22). Of the non-singleton CNVs, half 
(8/16) had a single pair of breakpoints in homologous parts of the segmental duplication, 
consistent with formation via non-allelic homologous recombination (NAHR; Fig. 1C). Of 
these, four share a breakpoint position, which coincides with a double-strand break 
(DSB) hotspot active in a PRDM9 C allele carrier ((24); Figs. 1C, S8). 
 
CNVs in the glycophorin region were observed more frequently in Africa than other parts 
of the world (Fig. 1D). In this dataset, the combined allele frequency of glycophorin 
CNVs in African populations was 11% compared to 1.1% in non-African populations, and 
most of the non-singleton CNVs (13/16) were identified in individuals of African ancestry. 
Among fourteen different ethnic groups sampled in Africa, the estimated frequency 
ranged from 4.7-21% with the highest frequencies in west African populations. 
 
Association with severe malaria 
We sought to incorporate CNVs into the phased reference panel with the aim of imputing 
into our GWAS dataset. Computational phasing of CNVs is challenging, as published 
methods do not model CNV mutational mechanisms or non-diploid copy number at 
smaller variants within CNVs. To work around this, we excluded SNPs and short indels 
within the glycophorin region and relied on the trio structure of sequenced individuals to 
resolve haplotype phase between CNVs and flanking SNPs (18, 25). Haplotype 
clustering and cross-validation predict good imputation performance for the three highest 
frequency CNVs, DEL1, DEL2, and DUP1 as well as for DUP4 (Figs. S9, S10, S11). 
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We used this panel to impute CNVs into the severe malaria GWAS samples and tested 
for association as before (Fig. S12). One of the imputed CNVs, DUP4, is associated with 
decreased risk of severe malaria (odds ratio, OR=0.60; 95% CI 0.50-0.72, P = 9.9x10-8 
using an additive model with fixed-effect meta-analysis across populations; Fig. 2). 
Across populations, evidence for association at DUP4 is among the strongest of any 
variant in our data. Moreover, conditioning on the imputed genotypes at DUP4 in the 
statistical association model removes signal at all other strongly associated variants 
including the previously reported markers of association (e.g., Pconditional=0.32 at 
rs186873296; Figs. 2F, S13). DUP4 has an estimated heterozygous relative risk of 0.61 
(95% CI 0.50-0.75) and its genetic effect appears to be consistent with an additive 
model, although the low frequency of homozygotes makes it difficult to distinguish the 
extent of dominance (homozygous relative risk 0.31; 95% CI 0.09-1.06; n=24 
homozygotes). Analysis of different clinical forms of severe malaria showed that DUP4 
reduced the risk of both cerebral malaria and severe malarial anaemia to a similar 
degree (Table S7). We noted some evidence of additional associations in the region, 
including a possible protective effect of DEL2 (OR=0.63; 95%CI=0.42-0.94, P=0.02), but 
no evidence of association with the more common DEL1, or with GYPB deletion status 
overall (P>0.1). These results are compatible with a primary signal of association that is 
well explained by an additive effect of DUP4. 
 
DUP4 is imputed with high confidence in both east African populations (Fig. 2D), where 
it is at substantially higher frequency than in the reference panel (Fig. S12). To 
independently confirm the imputed DUP4 genotypes, we analyzed SNP microarray data 
for intensity patterns indicative of copy number variation (Fig. 3) using a Bayesian 
clustering model informed by the sequenced DUP4 carriers (Fig. S14, Table S8) (22). 
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Classification of GWAS samples was highly concordant with the imputed DUP4 
genotypes in the east African populations (r2=0.96 in Kenya; r2=0.88 in Malawi; Table 
S9). Surprisingly, both imputation and the microarray intensity analysis suggest there 
may be no copies of DUP4 present among the 4791 Gambian individuals in the GWAS. 
This large frequency difference places DUP4 as an outlier compared with imputed 
variants at a similar frequency in the Gambia or in Kenya genome-wide (empirical 
P=1.7x10-3 and P=5x10-3, respectively; Fig. 4A). Computation of haplotype 
homozygosity (Fig. 4C) provides evidence that DUP4 is carried on an extended 
haplotype (empirical P=0.012 for iHS (26, 27) compared with variants of similar 
frequency genome-wide; Fig. 4D) that may have risen to its current frequency in Kenya 
relatively recently. We note that DUP4 is also absent from all but two of the reference 
panel populations (Fig. 1D). 
 
The physical structure of DUP4 
The copy number profile of DUP4 is complex, with a total of six copy number changes 
that cannot have arisen by a single unequal crossover event from reference-like 
sequences (Figs. 1A, 3B). At the gene level, this copy number profile corresponds to 
duplication of GYPE, deletion of the 3’ end of GYPB, duplication of the 5’ end of GYPB 
and triplication of the 3’ end of GYPA. To begin to understand the functional 
consequences of DUP4, we sought to reconstruct the physical arrangement of this 
variant by pooling data across the nine carriers in the sequenced reference panel (eight 
Wasambaa individuals from Tanzania including three parent-child pairs, and a single 
African Caribbean individual from Barbados). First, analysis of coverage along a multiple 
sequence alignment of the segmental duplication corroborated the location of the six 
copy number changes from the HMM, with two pairs of breakpoints at homologous 
locations in the alignment (Fig. S15). 
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Next, we looked for sequenced read pairs spanning CNV breakpoints, which provide 
direct evidence of the structure of the underlying DNA. We identified read pairs that were 
mapped near breakpoints but with discordant positions (MQ>=1, absolute insert size > 
1000 bp), including longer read data we generated for the 1000 Genomes individual who 
carries DUP4 (HG02554; 300 bp PE reads on Illumina MiSeq to 13x coverage). 
Discordant read pairs supported the connection between each pair of homologous 
breakpoints as well as between the remaining two breakpoints, which lie in non-
homologous sequence (Figs. 5A, S16). On the basis of the combined evidence from 
copy number changes, discordant read pairs, and homology between inferred 
breakpoints, we generated a model of the DUP4 chromosome that contains five 
glycophorin genes (Fig. 5B). 
 
A prominent functional change on this structure is the presence of two GYPB-A hybrid 
genes, supported by several read pairs within intron 4 of GYPA and GYPB and the copy 
number profile. We confirmed the hybrid sequence by PCR-based Sanger sequencing of 
a 4.1 kb segment spanning the breakpoint (Figs. 5B, S17, S18 and Table S10) (22). 
These data localize the breakpoint to a 184 bp section of GYPA and GYPB where the 
two genes have identical sequence (Fig. S19). If translated, the encoded protein would 
join the extracellular domain of GYPB to the transmembrane and intracellular domains of 
GYPA, creating a peptide sequence at their junction that is characteristic of the Dantu 
antigen in the MNS blood group system (Fig. 5D) (28, 29). Moreover, like DUP4, the 
most common Dantu variant (termed NE type, here referred to as Dantu NE) is reported 
to have two such hybrid genes and lack a full GYPB gene (30). We sequenced genomic 
DNA from an individual serologically determined to be Dantu positive, and of NE type 
(150 bp PE reads on Illumina HiSeq to 18x coverage) and analyzed it using our HMM. 
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The coverage profile and HMM-inferred copy number path, indistinguishable from those 
of DUP4 carriers, confirm identification of DUP4 as the molecular basis of Dantu NE 
(Fig. 5C). 
 
In addition to duplicate GYPB-A hybrid genes, these data reveal the full structure of this 
Dantu variant, including a duplicated copy of GYPE and the precise location of six 
breakpoints. Either complex mutational events or a series of at least four unequal 
crossover events are needed to account for the formation of this variant (confirmed by 
simulation; Fig. S20) (22). However, we find no potential intermediates and no obvious 
relationship between DUP4 and other structural variant haplotypes in the present 
dataset (Fig. S9) (22). Further analysis of discordant read pairs identifies a number of 
shorter discrepancies relative to the reference sequence that are consistent with gene 
conversion events (Fig. S21) and could be functionally relevant (e.g., Fig. S22). 
 
 
Discussion 
Here we use whole-genome sequence data to identify at least 27 CNVs in the 
glycophorin region that segregate in global populations. In this study, 14% of sub-
Saharan African individuals carry a variant that affects the genic copy number relative to 
the reference assembly. Our description of these variants complements the existing 
literature on antigenic variation associated with the MNS blood group system and offers 
additional insights. For example, the frequency of GYPB deletion is broadly 
commensurate with previous surveys of the S−s−U− blood group phenotype linked to 
absence of the GYPB protein, but the GYPB deletions in our data differ from the 
reported molecular variant (Fig. S23) (16, 22, 31-33). 
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Of the array of glycophorin CNVs identified, one (DUP4) is associated with resistance to 
severe malaria and explains the previously reported signal of association (14). While 
there may be other functional mutations on this haplotype, we propose that the direct 
consequences of this rearrangement are likely to drive the underlying causal mechanism 
for resistance to severe malaria. DUP4 was not present in the 1000 Genomes Phase 1 
reference panel (used in (14)), and exists as a singleton in the 1000 Genomes Phase 3 
reference panel. Thus, as previously observed at the sickle cell locus (34), mapping of 
the association signal by imputation was only possible with the inclusion of additional 
individuals in the reference panel.  
 
Through additional sequencing, we have shown that DUP4 corresponds to the variant 
encoding the Dantu+ (NE type) blood group phenotype, thus linking the predicted hybrid 
genes to a serologically distinct hybrid protein that is expressed on the red blood cell 
(29, 35). The few existing studies of Dantu+ (NE type) erythrocytes indicate high levels 
of the hybrid GYPB-A protein and lower levels of GYPA than wild type cells (35, 36). A 
single study reports parasite growth to be impaired in Dantu+ cells (37), making Dantu 
NE one of many glycophorin variants that have been hypothesized to influence malaria 
susceptibility or shown to have an effect in vitro (12, 37-40). Our results regarding a 
specific protective effect of DUP4, and the lack of evidence for other protective CNVs, 
suggest the relevance of these effects in natural populations may be complicated. We 
caution that many of the other CNVs are rare, such that larger sample sizes and direct 
typing may be required to test their effect in vivo. 
 
These findings then raise the question of how DUP4 protects against malaria. GYPA and 
GYPB are exclusively expressed on the erythrocyte surface and are targeted by 
parasites during invasion (6, 7). P. falciparum EBA175 binds to the extracellular portion 
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of GYPA (41), which is preserved in DUP4. P. falciparum EBL1 binds to the extracellular 
portion of GYPB (42) which is duplicated in DUP4 but joined to intracellular GYPA. The 
significance of the extra copy of GYPE or the absence of full GYPB in DUP4 is 
uncertain, since GYPE is not known to be expressed at the protein level (8, 43), and we 
do not observe evidence that absence of GYPB alone confers protection (Fig. 2A). 
GYPA and GYPB are known to form homodimers as well as heterodimers in the red cell 
membrane (33), so these copy number changes could have complex functional effects. 
There are physical interactions between GYPA and band 3 (encoded by SLC4A1) at the 
red cell surface (44) and parasite binding to GYPA appears to initiate a signal leading to 
increased membrane rigidity (45). Thus the GYPB-A hybrid proteins seen in DUP4 could 
potentially affect both receptor-ligand interactions and the physical properties of the red 
cell membrane. 
 
Previous surveys of the Dantu blood group antigen have indicated that it is rare ((33, 46-
48); Table S11). We find that DUP4 is absent or at very low frequency outside parts of 
east Africa, with a frequency difference and extended haplotype consistent with a recent 
rise in frequency in Kenya. In contrast, the malaria-protective variant causing sickle-cell 
anaemia (rs334 in HBB), which is thought to be under balancing selection, has a similar 
frequency in both the Gambia and Kenya (Fig. 4A). One possibility for why DUP4 is not 
more widespread, given its strong protective effect against malaria, is that it has arisen 
recently without time for gene flow to facilitate its dispersion. Alternatively, this frequency 
distribution could be consistent with balancing selection, for example if it protects only 
against certain strains of P. falciparum that are specific to east Africa. The glycophorin 
region is near a signal of long-term balancing selection, and measures of polymorphism 
in both the human glycophorins and P. falciparum EBA175 have been suggestive of 
diversifying selection (11, 12, 49, 50) (11-13, 49, 50). Although apparently not directly 
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related to these signals, current selection on DUP4 may represent a snapshot of the 
long-term evolutionary processes acting at this locus. Mapping the allele frequency of 
DUP4 across additional populations could help clarify the nature of selection. 
 
Recent GWAS have confirmed three other loci associated with severe malaria (HBB, 
ABO, ATP2B4), all of which are also related to red blood cell function (14, 51). However, 
only the association with GYPA and GYPB directly involves variation in invasion 
receptors. These receptors have been found to be non-essential in experimental models 
(7, 9), yet this result indicates important functional roles in natural populations. 
Intriguingly, there is marked variation among P. falciparum strains in preference for 
different invasion pathways in vitro (7); field studies that account for parasite 
heterogeneity and tests for genetic interactions may therefore be important in 
determining how DUP4 affects parasite invasion. The discovery that a specific alteration 
of these invasion receptors confers substantial protection provides a foundation for 
experimental studies on the precise functional mechanism, and may lead us towards 
novel parasite vulnerabilities that can be utilized in future interventions against this 
deadly disease. 
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Fig. 1. Copy number variants in the glycophorin region. (A) Sequence coverage in 
1600 bp windows and copy number for non-singleton CNVs. Black dashes show the 
mean normalized sequence coverage across heterozygous individuals not carrying 
another CNV. Only windows input to the HMM are shown. The inferred CNVs are 
indicated with deletion in yellow, duplication in light blue, and triplication in dark blue. A 
horizontal gray line indicates the expected coverage without copy number variation and 
blue vertical lines mark the locations of the three genes. (B) Mappability in the 
glycophorin region. (i) the number of mappable sites in each window; (ii) the maximum 
identity with the homologous locations in the segmental duplication in each window, as 
inferred from a multiple sequence alignment, with mean of 0.96 indicated with a red 
dashed line; (iii) sequences of at least 100 bp that are unique to one (black) or two (grey) 
out of the three segmentally duplicated units; (iv) protein-coding genes; (v) location of 
the segmentally duplicated units. (C) Positions of breakpoints, colored as the variant 
names in (A) and shaded by whether the variant has a single pair of homologous 
breakpoints, a single pair of non-homologous breakpoints, or is a multi-segment CNV. 
The recombination rate from LD-based recombination maps (52, 53) and locations of 
DSB hotspots (24) are annotated below. (D) Frequency of each CNV in the sampled 
populations. Populations are grouped on the basis of geographical proximity; 
abbreviations can be found in Tables S1 and S3. 
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Fig. 2. Evidence of association. (A) The evidence for association at SNPs, short 
indels, and CNVs across the glycophorin region. P-values are computed by meta-
analysis across three African populations under an additive model of association. Points 
are colored by LD with DUP4 in east African reference panel populations. Directly typed 
SNPs are denoted with black plusses, and CNVs with diamonds. Black triangles 
represent SNPs where the association signal was previously reported and replicated in 
further samples. (B) CNV copy number profiles, as in Fig. 1A. (C) Protein-coding genes. 
(D) Comparison of IMPUTE info score and expected imputed allele frequency for the 
four annotated CNVs. (E) The evidence for association at DUP4. Colored circles and 
text show the estimated allele frequency of DUP4 in population controls and severe 
malaria cases. To the right is the odds ratio and 95% confidence interval for DUP4 
heterozygotes (diamonds) and homozygotes (circles) relative to non-carriers. The 
bottom two rows represent effect sizes in a fixed-effect meta-analysis. Sample sizes 
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(number of controls/number of cases) are denoted to the left. (F) Comparison of 
association test P-values conditioning on five principal components (y axis, as in panel 
(A)), and additionally conditioning on genotypes at DUP4 (x axis). 
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Fig. 3. The effect of DUP4 on SNP array intensities. (A) Normalized Illumina Omni 
2.5M intensity values at selected SNP assays across the glycophorin region for 
reference panel individuals (top row; N=367 individuals from Burkina Faso, Cameroon, 
and Tanzania) and Kenyan GWAS individuals (second row, N = 3,142). Blue and yellow 
points represent individuals heterozygous or homozygous for DUP4 respectively, as 
determined by the HMM in reference panel individuals and by imputation in Kenya 
(genotypes with posterior probability at least 0.75). Arrows denote the mapping location 
of these SNPs. (B) The copy number profile of DUP4. (C) Position of the glycophorin 
genes and exons. 
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Fig. 4. DUP4 frequency and haplotype homozygosity. (A) The empirical joint allele-
frequency spectrum for population controls in the Gambia and Kenya, in 0.5% frequency 
bins between 0 and 20%. The frequencies of DUP4 and rs334 are highlighted. 
Histograms show the frequency in the Gambia of SNPs in the DUP4 frequency bin in 
Kenya (8.5-9%, top) and the frequency in Kenya of SNPs in the DUP4 frequency bin in 
the Gambia (0-0.5%, right). (B) The estimated frequency of DUP4 in east African 
populations, shown with 95% confidence intervals and the number of haplotypes 
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sampled. Estimates are from population controls in the GWAS or from the HMM 
genotype calls in the reference panel (daggers). The dotted vertical line denotes the 
overall frequency of DUP4 in Kenyan controls. (C) Extended haplotype homozygosity 
(EHH) computed outward from the glycophorin region for DUP4 haplotypes and non-
DUP4 haplotypes in Kenya, after excluding other variants within the glycophorin region. 
Below, the distribution of unstandardized iHS for all typed SNPs within 1% frequency of 
DUP4 in Kenyan controls. (D) Recombination rate (52, 53) (E) The 272 haplotypes 
imputed to carry DUP4 in Kenya, clustered on 1 Mb extending in either direction from the 
glycophorin region, which is shaded in blue. The bar on the left depicts the population for 
each haplotype with colors as in panel (B). (F) A random sample of 272 non-DUP4 
haplotypes clustered on the same region. (G) Protein-coding genes.  
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Fig. 5. The structure of DUP4. (A) Discordant read pairs mapped near DUP4 copy 
number changes. Colored arrows represent read pairs from DUP4 carriers, with paired 
reads shown on the same horizontal line and the direction of the arrows depicting the 
strand and position as mapped to the human reference sequence. The number of such 
read pairs and distinct carriers is given to the left. A schematic of the reference 
sequence is below with colors indicating the segmentally duplicated units. Brackets 
delineate segments with different copy number in DUP4, numbered and labeled with 
their length to the nearest kb. (B) The structure of DUP4, inferred by connecting 
sequence at breakpoints based on sequence homology and discordant read pairs. 
Arrows depict the concordant positions of the read pairs in (A) on this structure, and the 
order of reference segments is shown below. Inset: detail of the inferred GYPB-A hybrid 
genes, indicating the positions of discordant read pairs (arrows), PCR primers (vertical 
red lines) and the resulting product (horizontal red line). (C) Normalized coverage in 
1600 bp windows (black) and HMM path (red) for a DUP4 carrier (top) and for an 
individual serotyped as Dantu+ (NE type; bottom), on the same x axis as (A). (D) Protein 
sequences of GYPA, GYPB, and the Dantu hybrid within the cell membrane depicting 
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the extracellular, transmembrane, and intracellular domains as visualised with protter 
(54). 
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Materials	and	methods	
	
Sample	collection	and	sequencing	
Sequencing	 of	 African	 individuals.	 Blood	 samples	 from	 a	 total	 of	 773	 healthy	individuals	 from	 10	 ethnic	 groups	 in	 four	 countries	 in	 sub-Saharan	 Africa	 were	collected	 by	MalariaGEN	partners	 (www.malariagen.net)	 and	 the	MRC	Unit	 in	 the	Gambia	 (http://www.cggh.org/collaborations/mrc-unit-the-gambia)	 as	 part	 of	ongoing	projects	 (Fig.	S1A	 and	Tables	 S1,	 S2).	 Individuals	were	 from	the	general	population,	 with	 most	 collected	 in	 family	 trios	 except	 in	 Burkina	 Faso	 where	individuals	 are	 unrelated.	 Genomic	 DNA	 was	 extracted	 and	 sequencing	 was	performed	on	Illumina	HiSeq	2000	at	the	Wellcome	Trust	Sanger	Institute	with	100	bp	 paired	 end	 reads	 to	 an	 average	 of	 10x	 coverage.	 Reads	 were	 mapped	 to	 the	GRCh37	 human	 reference	 genome	 with	 additional	 sequences	 as	 modified	 by	 the	1000	 Genomes	 Project	 (hs37d5.fa;	 (20)),	 using	 BWA	 (55)	with	 base	 quality	 score	recalibration	(BQSR)	and	local	realignment	around	known	indels	as	implemented	in	GATK	(56,	57).		
Sequence	data	curation.	We	used	GATK	HaplotypeCaller	to	compute	an	initial	set	of	genotype	 likelihoods	 across	 samples	 at	 a	 genome-wide	 set	 of	 variants,	 including	polymorphic	 sites	 from	 1000	 Genomes	 Phase	 3	 (58).	 We	 computed	 average	coverage	 across	 the	 genome	 for	 each	 individual	 using	 BEDTools	 genomecov	 (59)	and	 excluded	 seven	Bantu	 individuals	 from	Cameroon	with	 less	 than	 2x	 coverage	across	 the	 genome,	 and	 one	Wollof	 individual	 from	 the	 Gambia	with	 less	 than	 6x	coverage	and	greater	 than	10%	missing	 call	 rate	 in	 the	GATK	analysis.	All	 further	analyses	described	here	are	based	on	the	765	non-excluded	individuals.	We	 inferred	 the	sex	of	sequenced	samples	based	on	 the	ratio	of	X	chromosome	coverage	to	autosomal	coverage.	To	infer	family	relationships,	we	used	lcMLkin	(60)	to	 compute	 maximum	 likelihood	 pairwise	 kinship	 estimates	 from	 the	 GATK-estimated	genotype	likelihoods	at	a	thinned	set	of	~26,000	SNPs	genome-wide.	We	then	ran	PRIMUS	(61)	to	infer	pedigrees	from	the	kinship	estimates	and	compared	the	 inferred	 and	 reported	 relationships.	 Based	 on	 this	 we	 manually	 curated	 the	family	structure	of	sequenced	samples	by	removing	relationships	incompatible	with	trio	structure	(IBD1	<	0.9	for	parent-child	relationship),	swapping	three	individuals	between	trios	with	clear	sample	mixups,	and	exchanging	parental	labels	in	two	trios	to	be	 consistent	with	 the	 genetic	 sex	 of	 the	parents.	 The	 curated	dataset	 contains	207	trios,	16	duos,	and	115	individuals	without	nominal	close	relationships.	All	trios	and	duos	are	unrelated	to	each	other	except	for	one	extended	family	in	the	Wollof	from	 the	 Gambia,	 which	 consists	 of	 a	 quad	 (two	 parents	 and	 two	 children,	 here	encoded	as	two	trios),	where	one	of	the	children	is	a	parent	in	an	additional	trio.		
1000	Genomes	sequence	data.	The	2,504	individuals	from	26	populations	in	the	1000	Genomes	Phase	3	release	(20)	were	analyzed.	Bam	files	containing	reads	mapped	to	GRCh37	 were	 downloaded	 from	 the	 1000	 Genomes	 FTP	 site	(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data/;	Fig.	S1B	and	Table	S3).		
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Overview	of	the	glycophorin	region.	The	glycophorin	gene	cluster	on	chromosome	4	results	from	segmental	duplication	events	 in	 the	ancestor	 to	African	great	apes	(62)	and	 is	not	related	 in	sequence	to	
GYPC	on	chromosome	2.	By	aligning	segments	of	the	reference	sequence	against	one	another,	we	 identified	 the	region	of	 segmental	duplication,	here	referred	 to	as	 the	glycophorin	 region,	 as	 chr4:144,706,830-145,069,066,	 and	 the	 three	 paralogous	units	 of	 the	 segmental	 duplication	 as:	 GYPE	 unit,	 chr4:144,706,830-144,837,481;	
GYPB	 unit,	 chr4:144,837,482-144,947,716;	 GYPA	 unit,	 chr4:144,947,717-145,069,066.	Each	gene	occupies	~30	kb	toward	the	end	of	its	~120	kb	repeat	unit.	We	generated	a	multiple	sequence	alignment	of	the	reference	sequence	for	the	three	units	 by	 running	 kalign	 (63)	 with	 default	 parameters,	 and	 calculated	 pairwise	identity	in	1600	bp	windows	along	this	alignment	(Fig.	1B).	The	glycophorin	genes	are	transcribed	on	the	negative	strand,	and	we	adopt	the	convention	of	numbering	exons	and	introns	as	they	occur	 in	the	GYPA	transcript	(exon	3	 is	a	pseudoexon	in	
GYPB	and	exons	3	and	4	are	pseudoexons	in	GYPE).	We	focus	on	the	three	protein-coding	genes,	but	note	that	a	 long	noncoding	RNA	is	annotated	between	GYPE	and	
GYPB	(LOC101927636).	The	coordinates	here,	and	throughout	the	paper,	are	given	with	respect	to	GRCh37.		
Construction	of	a	regional	reference	panel	
Identification	of	polymorphic	sites	and	genotype	likelihood	computation.	To	construct	a	 regional	 reference	 panel	 we	 focused	 on	 the	 10	 Mb	 region	 chr4:140-150Mb,	including	 a	 500	 kb	 margin	 at	 either	 end.	 We	 first	 assembled	 a	 list	 of	 previously	identified	SNPs	and	short	indels	from	the	1000	Genomes	Phase	3	(20),	the	Illumina	Omni	 2.5M	 array,	 the	 ExAC	 project	 (64)	 and	 the	 European	 Variation	 Archive	(downloaded	 on	 24th	 February	 2016;	 www.ebi.ac.uk/eva/),	 totaling	 421,670	variants.	We	 then	 used	 freebayes	 v1.0.2	 (19)	 to	 calculate	 genotype	 likelihoods	 at	these	 sites	 as	well	 as	 at	 newly	 identified	 putatively	 polymorphic	 sites,	 across	 the	3,269	sequenced	individuals.	Freebayes	was	run	in	10	kb	chunks	across	the	region.	We	 filtered	 freebayes	output	 to	 include	all	 previously	 identified	variants	 and	high	quality	 novel	 variants,	 i.e.,	 novel	 variants	 with	 quality	 (QUAL)	 >	 1,	 presence	 of	supporting	 reads	 on	 both	 strands	 (SAF	 >	 0	 and	 SAR	 >	 0)	 and	 both	 sides	 of	 the	variant	 (RPL>1	 and	 RPR>1),	 and	 high	 quality	 per	 alternate	 observation	(QUAL/AO>10).	 In	 total,	 the	 filtered	 output	 contained	 424,909	 variants,	 of	 which	412,795	were	among	the	previously	identified	variants.		
Genotype	 calling	 and	 phasing.	We	 next	 aimed	 to	 generate	 a	 high-quality	 set	 of	genotype	calls	in	the	765	individuals	collected	by	MalariaGEN	partners.	We	focused	on	 sites	 with	 combined	 mean	 coverage	 between	 7.5x	 and	 13.5x,	 excluding	approximately	 4%	 and	 1%	 of	 variants	 with	 depth	 below	 or	 above	 this	 range	respectively,	and	restricted	to	variants	with	allele	count	at	least	2,	leaving	a	total	of	117,531	 variants.	 We	 produced	 an	 initial	 set	 of	 genotype	 calls	 at	 these	 variants	using	BEAGLE	4.0	(beagle.r1399;	(17))	without	specifying	family	information.	Based	on	the	initial	calls,	we	removed	variants	with	more	than	five	mendelian	errors	in	the	207	trios,	strong	evidence	for	deviation	from	Hardy-Weinberg	equilibrium	(PHWE	<	1x10-3	 in	 the	 542	 individuals	 without	 parents	 in	 the	 dataset)	 or	 more	 than	 one	
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alternate	allele.	We	then	re-ran	BEAGLE	on	the	remaining	set	of	111,167	variants,	including	family	information,	to	produce	genotype	calls.	We	phased	these	genotypes	using	 SHAPEIT2,	 specifying	 400	 selected	 and	 200	 random	 conditioning	 states,	 an	effective	 population	 size	 of	 17,469,	 and	 10	 burn-in,	 8	 pruning	 and	 50	 main	iterations,	and	including	trio	information.	Finally,	 to	 form	a	 joint	 reference	panel	across	all	 individuals,	we	merged	 the	phased	 haplotypes	 with	 the	 1000	 Genomes	 Phase	 3	 haplotypes	 (20)	 at	 the	overlapping	 set	 of	 variants.	 The	 merged	 reference	 panel,	 which	 contains	 96,676	variants	in	the	region	chr4:139.5-150.5Mb,	is	available	for	use	in	other	studies	(EGA	study	accession	EGAS00001002385).		
Imputation	and	association	testing	at	SNPs	and	short	indels	
Imputation	 and	 association	 testing.	 We	 used	 both	 the	 1000	 Genomes	 Phase	 3	reference	 panel	 (20)	 and	 the	 merged	 reference	 panel	 described	 above	 to	 impute	genotypes	into	the	previously	published	sets	of	severe	malaria	cases	and	population	controls	from	the	Gambia,	Kenya	and	Malawi	(14).	In	brief,	we	ran	IMPUTE2	(65,	66)	in	2	Mb	chunks,	using	Illumina	Omni	2.5M	genotype	calls	as	previously	described.	A	total	of	5,621	(the	Gambia),	5,203	(Malawi),	and	5,583	(Kenya)	genotyped	variants	were	included	in	the	11	Mb	region	considered.	We	specified	1,000	copying	states	(-k_hap	1000),	 an	effective	population	 size	of	20,000	 (-Ne	20000)	as	 recommended	for	African	populations,	and	a	buffer	region	of	500	kb.	We	removed	reference	panel	individuals	with	parents	in	the	panel	before	imputation.	We	 tested	 for	 association	 in	 each	 population	 under	 additive,	 dominant,	recessive	and	heterozygote	models	using	SNPTEST.	We	restricted	analysis	here	 to	severe	malaria	cases	with	nonzero	parasitaemia,	as	measured	by	blood	slide	at	the	time	 of	 admission,	 as	 this	 is	 likely	 to	 be	 the	most	 accurate	 phenotype.	We	meta-analyzed	 association	 results	 across	 populations	 as	 previously	 described	 (14),	computing	both	fixed-effect	meta-analysis	and	a	model-average	Bayes	factor	(BFavg)	(14).	Meta-analysis	results	under	the	two	reference	panels	for	imputation,	as	well	as	under	the	previously	published	1000	Genomes	Phase	1	reference	panel	imputation,	are	shown	in	Fig.	S2.			
Functional	annotation	of	 variants.	We	used	 Variant	 Effect	 Predictor	 (VEP;	 (67))	 to	annotate	 the	 functional	 consequences	 of	 all	 variants	with	 evidence	 of	 association	(BFavg>1).	 We	 noted	 one	 variant	 with	 VEP	 IMPACT	 rating	 ‘moderate’	 with	 some	evidence	 of	 association	 (rs147343123;	 nonsynonymous	 in	 exon	 1	 of	 GYPA,	predicted	 deleterious;	 association	 test	BFavg=17.34,	 P=1.4x10-3	 for	 1000	 Genomes	imputation;	BFavg=121.3,	P	 =	1.5x10-4	 for	 full	panel	 imputation)	 (Fig.	 S2).	We	also	noted	 that	 the	nonsynonymous	variant	 in	FREM3	exon	1	previously	 found	to	have	evidence	 of	 association	 (rs181620317;	 see	 (14)),	 is	 imputed	 at	 much	 lower	frequency	using	both	the	1000	Genomes	Phase	3	panel	and	the	full	reference	panel	(e.g.	 frequency	 =	 0.2%	 in	 Kenya	 using	 the	 full	 reference	 panel),	 and	 shows	 no	evidence	for	association	in	these	imputations	(P	>	0.1).		
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Identification	of	copy	number	variation	
Method	to	call	copy	number	variation.	To	identify	large	CNVs	across	the	glycophorin	region,	 we	 implemented	 a	 hidden	 Markov	 model	 (HMM)	 to	 infer	 the	 underlying	copy	number	 state	 from	 the	 observed	 read	 counts.	 The	 input	 to	 the	HMM	 is	 read	depth,	 averaged	 over	 sites	 in	 windows	 of	 fixed	 length	 (here,	 1600	 bp)	 for	 each	individual.	To	reduce	the	problems	with	mapping	in	the	region,	we	included	only	(i)	reads	with	at	least	a	mapping	quality	(MQ)	of	20;	(ii)	mappable	sites,	defined	as	sites	with	mappability	 >0.9,	 where	mappability	 of	 a	 site	 is	 the	mean	 value	 of	 the	 CRG	mappability	 track	 for	 all	 100-mers	 overlapping	 that	 site	 (21);	 (iii)	 windows	with	≥25%	 of	 sites	 fulfilling	 this	 criterion;	 windows	 with	 fewer	 mappable	 sites	 were	considered	uninformative.	We	modeled	 the	mean	 depth	 of	 coverage	 for	 individual	 i	 at	window	 j,	di,j,	as	normally	distributed	with	mean	and	variance	dependent	on	the	assumed	underlying	copy	number	k	(k=2	is	the	normal	diploid	state):		 !!,!  ~ !"#$ !2!!!! , !2 !! !   ! ∈  0,1,2,3,4 		For	 copy	 number	 k=0	 (homozygous	 deletion),	 we	 used	 a	 truncated	 normal	distribution	(truncated	at	0)	and	assigned	a	variance	of	0.04	 to	allow	for	spurious	mapping.	 To	 account	 for	 systematic	 variation	 in	 coverage	 along	 the	 genome,	 we	estimated	a	window-specific	factor	(wj)	proportional	to	how	much	individuals	with	no	 copy	 number	 variation	 (k=2)	 are	 above	 or	 below	 their	mean	 in	 that	 window.	These	 define	 the	 emission	 probabilities	 for	 the	 HMM.	We	 used	 a	 fixed	 transition	matrix	that	assumes	a	low	rate	of	switching	with	approximately	0.999	probability	of	remaining	 in	 the	 current	 copy	 number	 state;	 1x10-4	 for	 leaving	 the	 diploid	 state;	0.001	probability	of	returning	to	diploid	(k=2)	from	a	non-diploid	state;	and	1x10-5	probability	of	switching	among	non-diploid	states.		We	estimated	μi,	σi	and	wj	by	starting	with	an	initial	guess	assuming	everyone	to	be	diploid	across	 the	 region,	 and	 then	 running	 the	Viterbi	algorithm	separately	for	each	individual.	We	then	recalculated	μi	and	σi	for	each	individual,	only	including	windows	in	which	the	copy	number	is	inferred	to	be	2,	and	wj	for	each	window	only	including	individuals	in	which	the	copy	number	is	inferred	to	be	2.	We	iterated	this	algorithm	until	 no	 further	 changes	 in	 the	 inferred	 underlying	 copy	 number	 paths	were	observed	for	any	individuals.			
CNV	 calling	 in	 the	 3,269	 sequenced	 individuals.	 We	 applied	 the	 HMM	 method	described	above	to	the	full	set	of	3,269	individuals	with	sequence	data	in	an	850	kb	region	including	the	glycophorin	genes	(chr4:144.35-145.20Mb).	After	inferring	the	copy	number	state	paths	for	each	individual,	we	then	considered	variants	to	be	the	same	across	 individuals	 if	 the	direction	of	copy	number	change	was	 the	same	and	both	end	points	were	within	three	bins	of	each	other.	Heterozygous	triplications	and	homozygous	duplications	were	differentiated	by	looking	across	individuals;	variants	that	were	always	found	in	copy	number	state	5	were	attributed	as	triplications.	We	excluded	 copy	 number	 variable	 segments	 that	 covered	 only	 a	 single	 bin	 or	 were	
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outside	 the	 segmental	 duplication.	 We	 then	 considered	 copy	 number	 variable	segments	that	were	always	found	together	to	be	a	single	CNV,	and	manually	refined	the	few	other	copy	number	variable	segments	that	were	not	found	separately	from	other	CNVs	(22).	This	process	identified	16	non-singleton	variants	and	28	singleton	variants	(Figs.	1A,	S3),	although	we	note	several	caveats	about	the	singleton	CNVs	including	some	that	likely	correspond	to	more	common	variants	(22).	To	 validate	 the	 CNVs	 and	 genotype	 calls,	 we	 assessed	 inheritance	 in	 the	MalariaGEN	 trios	 and	 compared	 genotype	 calls	 for	 the	 1000	Genomes	 individuals	with	 those	 released	 in	 the	 1000	 Genomes	 Phase	 3	 paper	 on	 structural	 variants	(Table	 S4,	Fig.	 S4)	 (22,	23).	We	 also	 designed	 PCR	 primers	 on	 either	 side	 of	 the	DEL1	 variant	 and	 generated	 Sanger	 sequence	 that	 confirmed	 and	 localized	 this	breakpoint	(Figs.	S5,	S6	and	Table	S5)	(22).		
Phasing	and	imputation	of	CNVs		
Initial	phasing	of	CNVs.	We	 investigated	whether	CNVs	could	be	accurately	phased	relative	 to	 surrounding	 SNP	 variation	 in	 the	 regional	 reference.	 Collectively,	 non-singleton	CNVs	in	our	dataset	cover	a	total	of	350	kb	(Fig.	1A),	which	extends	over	most	of	the	region	of	segmental	duplication	surrounding	the	glycophorin	genes.	 In	principle,	inference	of	CNV	haplotype	phase	might	benefit	from	copy-number-aware	genotype	 calls	 at	 smaller	 variants	 within	 CNVs.	 However,	 implementing	 this	 is	challenging	as	 the	state-of-the	art	phasing	methods	assume	samples	are	diploid.	A	further	possible	issue	is	that	read	mapping,	and	hence	the	quality	of	SNP	genotype	calls,	is	likely	to	be	impaired	in	such	regions	of	segmental	duplication.	Motivated	by	 these	observations,	we	 took	 the	 following	approach	 to	phasing	CNVs	 which	 leverages	 the	 family	 trio	 structure	 of	 sequenced	 individuals	 to	 infer	accurate	phase,	using	both	SHAPEIT2	(18)	and	MVNCALL	(25).	First,	we	focused	on	the	 765	 sequenced	 individuals	 collected	 by	 MalariaGEN	 partners.	 We	 removed	variants	 within	 the	 region	 of	 segmental	 duplication	 (here	 taken	 as	 chr4:144.7-145.07Mb)	from	the	reference	panel,	and	replaced	these	with	CNV	genotype	calls,	to	form	 a	 single	 file	 with	 genotypes	 at	 the	 CNVs	 and	 flanking	 SNPs	 and	 indels.	SHAPEIT2	requires	each	variant	to	be	assigned	a	single	genomic	position.	For	each	CNV	longer	than	10	kb	we	included	the	genotypes	for	that	variant	at	the	start-,	mid-	and	endpoints	of	 the	CNV;	 for	variants	 less	 than	10	kb	we	used	 the	midpoint.	We	then	 ran	 SHAPEIT2	with	 parameters	 as	 for	 SNP/indel	 phasing	 to	 produce	 phased	genotype	calls,	treating	each	CNV	as	a	separate,	biallelic	variant.	Next,	to	phase	CNVs	into	the	1000	Genomes	Project	 individuals,	we	extracted	the	Omni	2.5M	sites	with	allele	 frequency	 >	 1%	 from	 the	 1000	 Genomes	 Project	 phased	 haplotypes	 and	removed	the	region	of	segmental	duplication.	We	used	MVNCALL	to	phase	each	non-singleton	CNV	into	this	scaffold,	again	placing	each	CNV	greater	than	10	kb	in	length	at	its	start-,	mid-,	and	end	positions.	We	assessed	accuracy	of	phasing	by	considering	patterns	of	LD	between	CNVs	and	variants	in	the	left	and	right	flanking	regions	(Figs.	S9,	S10).	We	noted	high	LD	between	some	CNVs	and	variants	to	the	left	of	the	region,	including	for	DEL1,	DEL2,	DUP1	 and	 DUP4.	 LD	 estimated	 from	 phased	 haplotypes	 captured	 most	 of	 the	correlation	 between	 genotypes	 across	 the	 region,	 as	 expected	 in	 an	 outbred	population	 if	 haplotype	 phase	 is	 accurate.	 The	 small	 deviations	 observed	may	 be	
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due	to	the	presence	of	a	small	number	of	switch	errors,	or	potentially	to	population	substructure.		
Haplotype-based	curation	and	re-phasing	of	CNVs.	Some	singleton	CNVs	have	similar	copy	number	profiles	to	more	common	CNVs	in	the	HMM-based	calls	(22)	and	after	phasing	we	observed	 that	 haplotypes	 carrying	 several	 of	 these	 clustered	with	 the	corresponding	common	variant	 (DEL9	with	DEL1;	DEL11,	DEL12	and	DEL14	with	DEL2;	 DUP15	 and	 DUP18	 with	 DUP1).	 We	 reasoned	 that	 these	 are	 likely	 to	represent	 the	 same	 variant,	with	 differences	 in	 calling	 potentially	 due	 to	 noise	 in	coverage	 profiles	 or	 variation	 in	 the	 other	 chromosome.	 We	 merged	 these	singletons	with	 the	 corresponding	non-singleton	CNV	and	 repeated	 the	procedure	described	 above,	 using	 SHAPEIT2	 and	 MVNCALL	 to	 re-phase	 CNVs	 and	 flanking	short	 variants	 then	 merging	 the	 two	 reference	 panels.	 We	 also	 noted	 that	haplotypes	 carrying	 DEL4	 cluster	 with	 DUP1,	 which	 shares	 a	 similar	 breakpoint	(Fig.	 1).	 A	 plausible	 explanation	 for	 this	 is	 that	 DUP1	 arose	 by	 NAHR	 on	 a	 DEL4	background	(Fig.	S24)	(22).	For	subsequent	imputation	steps	we	restricted	the	combined	panel	to	the	set	of	haplotypes	from	unrelated	individuals	(i.e.	removing	the	children	of	family	trios	and	 duos).	 	 Three	 individuals	 in	 the	 1000	Genomes	 data	 carry	 CNVs	 that	 are	 not	singletons	 in	the	overall	dataset	but	are	private	to	 that	 individual	within	the	1000	Genomes	data	 (HG01986,	 carrying	DEL4;	HG02554,	 carrying	DUP4,	and	HG02585,	carrying	DUP5).	Of	 these,	we	noted	 in	particular	 that	HG02554	appears	 to	have	 a	switch	 error	 in	 the	 1000	 Genomes	 (explaining	 clustering	 of	 opposite	 haplotypes	with	 other	 DUP4	 haplotypes	 on	 either	 side	 of	 the	 region;	 Fig.	 S9).	 Because	 our	approach	phases	variants	in	the	1000	Genomes	separately	and	these	are	singletons	in	 that	 dataset,	 we	 also	 excluded	 these	 three	 individuals	 from	 the	 panel	 used	 for	imputation.		
Cross-validation	of	CNV	imputation	in	the	reference	panel.	To	evaluate	how	well	CNVs	are	 likely	 to	 be	 imputed	 in	 our	 GWAS	 dataset,	 we	 performed	 a	 cross-validation	experiment	 using	 the	 African	 reference	 panel	 individuals	 as	 follows.	 For	 each	individual,	we	removed	the	individual	and	his/her	family	members	(if	present)	from	the	phased	reference	panel	haplotypes	to	form	a	subsetted	panel.	We	also	extracted	genotype	calls	for	that	individual	at	variants	on	the	Illumina	Omni	2.5M	array	from	the	reference	panel	genotypes,	excluding	variants	within	the	glycophorin	region.	We	used	these	genotypes	and	the	subsetted	panel	to	re-impute	CNVs	for	that	individual.	We	evaluated	CNV	re-imputation	by	computing	the	correlation	between	HMM-based	genotype	calls	and	genotype	dosages	 from	the	re-imputation	(Fig.	 S12)	and	by	 direct	 comparison	 of	 HMM	 and	 re-imputed	 calls.	 We	 note	 that	 DEL4	 carriers	were	 imputed	with	some	confidence	as	carrying	DUP1,	consistent	with	 the	shared	haplotype	 for	 these	 variants	 and	 the	 higher	 frequency	 of	 DUP1.	 Given	 the	functionally	distinct	nature	of	these	variants,	 this	affects	 interpretation	of	 imputed	DUP1	genotypes.	Among	 CNVs	 >10	 kb	 in	 length,	 we	 noted	 little	 variation	 between	 the	 three	imputation	 locations	 (leftmost	 breakpoint,	midpoint,	 and	 rightmost	 breakpoint	 of	the	CNV),	except	for	DUP4,	where	the	right	endpoint	had	slightly	higher	imputation	
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performance	 (Fig.	 S11).	 For	 all	 analyses	 presented	 in	 this	 paper	 we	 refer	 to	 the	midpoint	imputation	of	each	CNV.		
Imputation	 of	 CNVs.	We	 used	 the	 combined	 panel	 to	 impute	 CNVs	 into	 the	 three	GWAS	datasets.	Imputation	settings	were	as	described	above.	To	ensure	imputation	was	based	on	flanking	SNPs,	we	removed	SNPs	within	the	glycophorin	region	from	the	genotype	data	before	imputation.	We	evaluated	imputation	performance	in	the	GWAS	data	by	comparing	the	overall	expected	allele	frequency	against	the	IMPUTE	info	metric	and	another	metric	of	confidence	in	imputed	CNV	call	probabilities,	the	proportion	of	expected	frequency	of	CNV	heterozygote	or	homozygote	that	is	due	to	genotypes	 with	 at	 least	 90%	 probability	 (Fig.	 2D	 and	 Fig.	 S12A,B).	 We	 also	compared	 the	 expected	 frequency	 in	 control	 samples	 with	 the	 frequency	 in	 the	geographically	nearest	reference	panel	population	(Fig.	S12C).			
Analysis	of	association	at	CNVs	
Association	with	 severe	malaria.	We	 tested	 for	 association	 with	 each	 CNV	 in	 each	population	and	computed	both	fixed-effect	and	Bayesian	meta-analyses	as	for	other	variants.	To	directly	estimate	the	effect	of	heterozygote	and	homozygote	genotypes,	we	modified	SNPTEST	to	fit	the	logistic	regression	model	with	a	separate	parameter	for	heterozygote	and	homozygote	genotypes	in	a	missing	data	likelihood	framework	that	 integrates	over	 imputation	uncertainty.	To	do	conditional	 tests	of	association,	we	 used	 QCTOOL	 v2	 (http://www.well.ox.ac.uk/~gav/qctool_v2/)	 to	 extract	 the	additive	 and	 heterozygote	 imputed	 dosages	 of	 DUP4	 for	 each	 individual,	 and	repeated	the	association	test	and	meta-analysis	conditioning	on	these	dosages	(Figs.	
2F,	S13).		
Association	with	clinical	 subtypes.	Severe	malaria-affected	 children	 in	 our	 data	 are	recorded	as	either	having	cerebral	malaria	(CM),	severe	malarial	anaemia	(SMA),	or	other	nonspecific	severe	malaria	phenotype	(OTHER).	To	assess	 the	association	of	DUP4	with	these	subphenotypes,	we	fit	a	multinomial	logistic	regression	model	with	these	 outcome	 levels	 using	 population	 controls	 as	 a	 baseline	 (Table	 S7).	 A	 small	number	of	individuals	are	annotated	as	both	CM	and	SMA	and	were	excluded	from	this	analysis.		
Association	with	gene	content.	 To	 test	 for	 association	with	 overall	 copy	number	 of	each	 glycophorin	 gene,	we	 used	 the	 imputed	 genotype	 probabilities	 and	 the	 copy	number	profile	of	non-singleton	CNVs	(Fig.	1)	to	compute	the	expected	number	of	copies	of	each	gene	in	each	GWAS	sample.	Since	overlap	of	some	CNVs	with	genes	is	partial,	 we	 measured	 copy	 number	 separately	 at	 the	 transcription	 start	 and	 end	sites.	 	We	also	computed	the	expected	dosage	of	hybrid	genes	as	formed	by	DUP2,	DUP4	 and	 DUP8.	 	We	 tested	 for	 association	 across	 the	 three	 populations	 using	 a	logistic	regression	model	including	the	genic	dosage	and	five	principal	components	in	 each	 population.	 Overall	 genic	 copy	 number	 was	 significantly	 associated	 with	severe	malaria	status	(e.g.	P=3x10-7	 for	dosage	at	 transcription	start	sites),	as	was	the	dosage	of	hybrid	genes.		However,	these	effects	were	well	explained	by	the	effect	of	DUP4	 (P	>	0.14	after	 conditioning	on	expected	dosage	of	DUP4).	 	We	note	 that	
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several	of	these	predictors	are	strongly	correlated	with	DUP4	dosage;	this	analysis	could	not	distinguish	between	an	effect	of	DUP4	and	that	of	copy	number	of	GYPE,	copy	number	of	the	GYPA	transcription	end	site,	or	the	total	copy	number	of	hybrid	genes	(P	>	0.13	for	either	effect	in	a	joint	model).		We	 also	 specifically	 tested	whether	 the	 number	 of	 deleted	 copies	 of	GYPB,	 or	 the	presence	of	one	or	 two	deleted	copies,	was	associated	with	 severe	malaria	 status,	but	saw	no	evidence	of	association	(P>0.48).		
Population	genetic	analysis	
Frequency	differentiation.	We	used	estimated	minor	allele	frequencies	(MAF)	at	both	typed	 and	 imputed	 variants	 from	 (14)	 for	 the	 2,490	population	 controls	 from	 the	Gambia	and	1,498	population	controls	from	Kenya	to	investigate	the	extent	to	which	the	 observed	 frequency	 difference	 of	 DUP4	 is	 extreme	 relative	 to	 other	 variants	genome-wide.	 For	 this	 comparison,	 we	 included	 all	 autosomal	 variants	 having	IMPUTE	info	>0.75	and	estimated	frequency	≥0.5%	in	at	least	one	of	the	populations	(14,973,426	variants	in	total).	We	binned	variants	into	0.5%	MAF	bins	(Fig.	4A)	and	noted	the	frequency	estimates	for	DUP4	(fKenya=0.0895	and	 fGambia=0.0003)	and,	 for	comparison,	 the	sickle	cell	anaemia-causing	allele	 (rs334:T;	MAF=0.0853	 in	Kenya	and	 0.0766	 in	 the	 Gambia	 based	 on	 direct	 Sequenom	 typing	 of	 this	 SNP	 in	 these	samples	(68)).	To	quantify	the	extent	to	which	DUP4	is	an	outlier,	we	computed	two	empirical	
P-values	based	on	the	marginal	distributions.	Specifically,	we	computed	PGambia|Kenya	as	 the	proportion	of	variants	with	MAF	 less	 than	or	equal	 to	 fGambia	 in	 the	Gambia,	among	 all	 variants	 with	 MAF	 within	 1%	 of	 fKenya	 in	 Kenya	 (empirical	
PGambia|Kenya<1.2x10-6;	 0	 of	 831,956	 variants	 in	 this	 bin).	 Similarly,	 we	 computed	
PKenya|Gambia	as	the	proportion	of	variants	with	MAF	equal	to	or	greater	than	fKenya	in	Kenya,	 among	all	 variants	with	MAF	within	1%	of	 fGambia	 in	 the	Gambia	 (empirical	
PKenya|Gambia=1.7x10-3;	2,851	of	1,710,922	variants	in	this	bin).	We	 note	 that	 the	 computation	 of	PGambia|Kenya	 is	 sensitive	 to	 the	 frequency	 of	DUP4	 in	 the	 Gambia,	 which	 may	 be	 underestimated	 due	 to	 poor	 imputation	performance.	 To	 account	 for	 this	 we	 recomputed	 PGambia|Kenya	 assuming	 1%	frequency	 in	 the	 Gambia	 (adjusted	 empirical	PGambia|Kenya=5x10-3)	 and	 refer	 to	 this	value	in	the	main	text.		
Haplotype	homozygosity.	To	assess	haplotype	homozygosity,	we	first	used	SHAPEIT2	to	phase	imputed	CNV	genotypes	onto	haplotypes	defined	by	directly-typed	SNPs	in	the	 region	 chr4:139.5-150.5Mb,	 excluding	 SNPs	 in	 the	 glycophorin	 region.	 We	specified	 400	 selected	 and	 200	 random	 copying	 states	 (--states	 400,	 --states-random	 200),	 an	 effective	 population	 size	 of	 17,469	 as	 recommended	 for	 African	populations,	and	included	reference	panel	haplotypes	to	 inform	phasing.	EHH	(27)	was	then	computed	around	DUP4	using	the	rehh	R	package.	We	used	a	custom	script	to	 compute	 an	 unstandardized	 integrated	 haplotype	 score	 (uiHS)	 (26),	 using	recombination	rate	estimates	from		the	HapMap	combined	recombination	map	(52).	To	generate	a	distribution	of	uiHS	at	SNPs	with	a	similar	 frequency	to	DUP4,	we	computed	uiHS	at	those	genotyped	SNPs	(14)	where	the	human	ancestral	allele	
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could	 be	 inferred	 using	 the	 six	 primate	 EPO	 alignments	(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/ancestral_alignments/),	and	the	derived	allele	frequency	was	in	the	2%	frequency	bin	centered	 around	 fKenya	 (0.0795-0.0995).	We	 computed	 an	 empirical	P-value	 as	 the	proportion	 of	 SNPs	 with	 uiHS	 less	 than	 or	 equal	 to	 that	 observed	 at	 DUP4	(P=0.0119;	996	of	the	83,419	variants	in	this	bin).	We	note	that	the	exclusion	of	the	glycophorin	region	from	the	estimate	at	DUP4	is	 likely	to	be	conservative,	since	in	effect	 it	 adds	 a	 constant	 term	 equal	 to	 the	 recombination	 length	 of	 the	 removed	interval	 (approximately	 0.15	 cM)	 to	 both	 the	 numerator	 and	 denominator	 of	 the	statistic.		
Resolution	of	the	structure	of	DUP4	
Discordant	read	pair	analysis.	We	began	by	remapping	reads	from	each	of	 the	nine	heterozygous	 DUP4	 carriers	 genome-wide	 using	 bwa	 mem,	 which	 has	 better	performance	for	longer	reads	(69).	Because	even	longer	reads	should	facilitate	more	confident	mapping	around	the	breakpoints,	we	also	obtained	DNA	from	Coriell	 for	HG02554,	 the	 1000	 Genomes	 sample	 carrying	 DUP4,	 and	 generated	 300	 bp	 PE	sequence	 data	 on	 Illumina	 MiSeq	 at	 the	 High	 Throughput	 Genomics	 core	 at	 the	Wellcome	Trust	Centre	for	Human	Genetics	at	the	University	of	Oxford.	We	mapped	these	 reads	 to	 the	 same	 GRCh37	 human	 reference	 (hs37d5.fa)	 with	 bwa	 mem,	yielding	13x	genomic	coverage.	For	all	re-mapped	bam	files,	we	marked	duplicates	with	Picard	MarkDuplicates	and	excluded	duplicate	reads	from	further	analysis.	We	then	used	samtools	to	pull	out	read	pairs	where	both	reads	had	a	primary	alignment	 to	 the	glycophorin	region	with	MQ≥1	and	an	absolute	 insert	size	≥1	kb.	For	 the	300	bp	data,	we	allowed	one	of	 the	reads	 in	 the	pair	 to	be	mapped	 to	 the	glycophorin	region	with	MQ=0.	Across	samples,	there	were	434	such	read	pairs.	We	grouped	 read	pairs	where	both	ends	were	mapped	within	1	kb	of	 each	other	 and	identified	those	near	the	HMM-inferred	breakpoints.	To	 view	 how	 uniquely	 the	 discordant	 read	 pairs	matched	 each	 of	 the	 three	possible	homologous	positions	 in	 the	 segmental	 duplication,	we	used	 the	mapped	position	and	the	cigar	string	to	place	each	read	into	the	multiple	sequence	alignment	and	 then	 identified	positions	 in	 the	read	with	a	match	or	mismatch	 to	each	of	 the	three	aligned	reference	sequences	using	custom	scripts	in	R	(e.g.,	Fig.	S16).	
	
Molecular	 assays	 and	 Sanger	 sequencing.	 Briefly,	 a	 4.1	 kb	 fragment	 spanning	 the	
GYPB-A	hybrid	breakpoint	 (located	between	exons	4	and	5)	was	amplified	by	PCR	using	primers	designed	against	GYPB	and	GYPA	sequences.	In	practice,	it	is	difficult	to	design	 specific	 primers	due	 to	 the	high	homology	 and	 the	 assay	 amplifies	both	
GYPA	and	GYPB-A	hybrid	 sequences.	To	 separate	 these,	we	 identified	 a	 restriction	enzyme	site	(BlpI	[5'…GC/TNAGC…3'])	that	cleaves	the	GYPA	sequence	but	not	that	of	the	hybrid.	PCR	products	were	digested	and	then	separated	on	an	agarose	gel.	We	excised	 the	 4.1	 kb	 band	 and	 obtained	 Sanger	 sequence	 of	 the	 region	 around	 the	putative	breakpoint.	A	full	description	of	the	design,	primers	and	protocols	is	given	in	(22).			
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Sequencing	and	copy	number	analysis	of	a	serologically-typed	Dantu+	individual.	We	obtained	DNA	from	the	International	Blood	Group	Reference	Laboratory	in	Bristol,	UK	from	an	archived	reference	sample	that	had	been	serologically	typed	as	Dantu+	(NE	type).	This	sample	was	collected	in	1992	and	the	individual	was	originally	from	Natal,	South	Africa.	The	DNA	was	sequenced	with	150	bp	PE	reads	on	Illumina	HiSeq	4000	 by	 the	 High	 Throughput	 Genomics	 core	 at	 the	 Wellcome	 Trust	 Centre	 for	Human	 Genetics	 at	 the	 University	 of	 Oxford.	 Reads	 were	 mapped	 to	 the	 same	GRCh37	 human	 reference	 genome	 (hs37d5.fa)	 with	 bwa	 mem,	 yielding	 18x	coverage.	To	generate	CNV	calls,	we	ran	our	HMM	method	on	this	individual	alone,	without	using	the	window-specific	factors.		
Simulations	of	DUP4	formation.	To	determine	possible	routes	to	formation	of	DUP4,	we	 implemented	 a	 computer	 program	 in	 C++	 to	 iteratively	 generate	 structural	rearrangements	via	unequal	crossing	over,	allowing	breakpoints	to	occur	at	any	of	the	six	locations	observed	for	DUP4	with	no	constraint	based	on	homology.	In	brief,	we	encode	the	reference	haplotype	as	a	string	of	seven	segments	delineated	by	the	coverage	 breakpoints	 (i.e.,	 as	 the	 string	 0123456;	 Fig.	 5A).	 We	 ran	 the	 program	through	 three	 generations	 of	 events,	 where	 the	 first	 generation	 produced	 all	possible	 events	 between	 two	 reference	 haplotypes	 and	 the	 second	 and	 third	generations	 allowed	 unequal	 crossing	 over	 between	 any	 two	 haplotypes	 from	previous	generations.	This	brute	force	search	allows	us	to	place	a	lower	limit	of	four	on	 the	 number	 of	 events	 required	 to	 form	 DUP4.	 	 For	 additional	 details	 on	 the	program	and	search,	see	(22).	
